[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[S. 981 Introduced in Senate (IS)]
111th CONGRESS
1st Session
S. 981
To support research and public awareness activities with respect to
inflammatory bowel disease, and for other purposes.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
May 5, 2009
Mr. Reid introduced the following bill; which was read twice and
referred to the Committee on Health, Education, Labor, and Pensions
_______________________________________________________________________
A BILL
To support research and public awareness activities with respect to
inflammatory bowel disease, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Inflammatory Bowel Disease Research
and Awareness Act''.
SEC. 2. FINDINGS.
Congress finds the following:
(1) Crohn's disease and ulcerative colitis are serious
inflammatory diseases of the gastrointestinal tract.
(2) Crohn's disease may occur in any section of the
gastrointestinal tract but is predominately found in the lower
part of the small intestine and the large intestine. Ulcerative
colitis is characterized by inflammation and ulceration of the
innermost lining of the colon. Complete removal of the colon in
patients with ulcerative colitis can potentially alleviate and
cure symptoms.
(3) Because Crohn's disease and ulcerative colitis behave
similarly, they are collectively known as inflammatory bowel
disease. Both diseases present a variety of symptoms, including
severe diarrhea, abdominal pain with cramps, fever, arthritic
joint pain, inflammation of the eye, and rectal bleeding. There
is no known cause of inflammatory bowel disease, or medical
cure.
(4) It is estimated that up to 1,400,000 people in the
United States suffer from inflammatory bowel disease, 30
percent of whom are diagnosed during their childhood years.
(5) Children with inflammatory bowel disease miss school
activities because of bloody diarrhea and abdominal pain, and
many adults who had onset of inflammatory bowel disease as
children had delayed puberty and impaired growth and have never
reached their full genetic growth potential.
(6) Inflammatory bowel disease patients are at high risk
for developing colorectal cancer.
(7) The total annual medical costs for inflammatory bowel
disease patients are estimated at more than $2,000,000,000.
(8) The average time from presentation of symptoms to
diagnosis in children is 3 years.
(9) Delayed diagnosis of inflammatory bowel disease
frequently results in more-active disease associated with
increased morbidity and complications.
(10) Congress has appropriated $3,480,000 from fiscal year
2005 to fiscal year 2009 for epidemiology research on
inflammatory bowel disease through the Centers for Disease
Control and Prevention.
(11) The National Institutes of Health National Commission
on Digestive Diseases issued comprehensive research goals
related to inflammatory bowel disease in its April 2009 report
to Congress and the American public entitled; ``Opportunities
and Challenges in Digestive Diseases Research: Recommendations
of the National Commission on Digestive Diseases''.
SEC. 3. ENHANCING PUBLIC HEALTH ACTIVITIES ON INFLAMMATORY BOWEL
DISEASE AT THE CENTERS FOR DISEASE CONTROL AND
PREVENTION.
Part B of title III of the Public Health Service Act (42 U.S.C. 243
et seq.) is amended by inserting after section 320A the following:
``SEC. 320B. INFLAMMATORY BOWEL DISEASE EPIDEMIOLOGY PROGRAM.
``(a) In General.--The Secretary, acting through the Director of
the Centers for Disease Control and Prevention, shall conduct, support
and expand existing epidemiology research on inflammatory bowel disease
in both pediatric and adult populations.
``(b) Grants.--The Secretary, acting through the Director of the
Centers for Disease Control and Prevention, may award grants to, and
enter into contracts and cooperative agreements with, a patient or
medical organization with expertise in conducting inflammatory bowel
disease research to develop and administer the epidemiology program.
``(c) Rule of Construction.--Nothing in this section shall be
construed to limit the authority of the Centers for Disease Control and
Prevention to support a pediatric inflammatory bowel disease patient
registry.
``(d) Authorization of Appropriations.--There are authorized to be
appropriated to carry out this section, $1,500,000 for each of the
fiscal years 2010 through 2014.
``SEC. 320C. INCREASING PUBLIC AWARENESS OF INFLAMMATORY BOWEL DISEASE
AND IMPROVING HEALTH PROFESSIONAL EDUCATION.
``(a) In General.--The Secretary, acting through the Director of
the Centers for Disease Control and Prevention, shall award grants to
eligible entities for the purpose of increasing awareness of
inflammatory bowel disease among the general public and health care
providers.
``(b) Use of Funds.--An eligible entity shall use grant funds under
this section to develop educational materials and conduct awareness
programs focused on the following subjects:
``(1) Crohn's disease and ulcerative colitis, and their
symptoms.
``(2) Testing required for appropriate diagnosis, and the
importance of accurate and early diagnosis.
``(3) Key differences between pediatric and adult disease.
``(4) Specific physical and psychosocial issues impacting
pediatric patients, including stunted growth, malnutrition,
delayed puberty, and depression.
``(5) Treatment options for both adult and pediatric
patients.
``(6) The importance of identifying aggressive disease in
children at an early stage in order to implement the most
effective treatment protocol.
``(7) Complications of inflammatory bowel disease and
related secondary conditions, including colorectal cancer.
``(8) Federal and private information resources for
patients and physicians.
``(9) Incidence and prevalence data on pediatric and adult
inflammatory bowel disease.
``(c) Eligible Entity.--For purposes of this section, the term
`eligible entity' means a patient or medical organization with
experience in serving adults and children with inflammatory bowel
disease.
``(d) Report to Congress.--Not later than September 30, 2010, the
Secretary shall submit to the Committee on Energy and Commerce of the
House of Representatives, the Committee on Health, Education, Labor,
and Pensions of the Senate, and the Committee on Appropriations of the
House of Representatives and the Senate, a report regarding the status
of activities carried out under this section.
``(e) Authorization of Appropriations.--For the purpose of carrying
out this section, there is authorized to be appropriated such sums as
may be necessary for each of fiscal years 2010 through 2014.''.
SEC. 4. EXPANSION OF BIOMEDICAL RESEARCH ON INFLAMMATORY BOWEL DISEASE.
(a) Sense of Congress.--It is the sense of Congress that--
(1) the Secretary of Health and Human Services, acting
through the Director of the National Institutes of Health and
the Director of the National Institute of Diabetes and
Digestive and Kidney Diseases (in this section referred to as
the Institute), should aggressively support basic,
translational, and clinical research designed to meet the
research goals for inflammatory bowel disease included in the
National Institutes of Health National Commission on Digestive
Diseases report entitled ``Opportunities and Challenges in
Digestive Diseases Research: Recommendations of the National
Commission on Digestive Diseases'', which shall include--
(A) establishing an objective basis for determining
clinical diagnosis, detailed phenotype, and disease
activity in inflammatory bowel disease;
(B) developing an individualized approach to
inflammatory bowel disease risk evaluation and
management based on genetic susceptibility;
(C) modulating the intestinal microflora to prevent
or control inflammatory bowel disease;
(D) effectively modulating the mucosal immune
system to prevent or ameliorate inflammatory bowel
disease;
(E) sustaining the health of the mucosal surface;
(F) promoting regeneration and repair of injury in
inflammatory bowel disease;
(G) providing effective tools for clinical
evaluation and intervention in inflammatory bowel
disease; and
(H) ameliorating or preventing adverse effects of
inflammatory bowel disease on growth and development in
children and adolescents;
(2) the Institute should support the training of qualified
health professionals in biomedical research focused on
inflammatory bowel disease, including pediatric investigators;
and
(3) the Institute should continue its strong collaboration
with medical and patient organizations concerned with
inflammatory bowel disease and seek opportunities to promote
research identified in the scientific agendas ``Challenges in
Inflammatory Bowel Disease Research'' (Crohn's and Colitis
Foundation of America) and ``Chronic Inflammatory Bowel
Disease'' (North American Society for Pediatric
Gastroenterology, Hepatology and Nutrition).
(b) Biennial Reports.--As part of the biennial report submitted
under section 403 of the Public Health Service Act (42 U.S.C. 283), the
Secretary of Health and Human Services shall include information on the
status of inflammatory bowel disease research at the National
Institutes of Health.
<all>